Volume 96 Issue 11 | pp. 32-34
Issue Date: March 12, 2018

Cultural change at a midwestern pharmaceutical chemical plant

Evonik claims success in turning a Lilly drug plant into a multicustomer services facility
Department: Business
Keywords: Outsourcing, high-potency API, fermentation, pharmaceuticals

Evonik Industries declared victory for its exclusive synthesis division late last year when it announced the renewal of a long-term supply contract with Eli Lilly & Co.

The German firm bought Lilly’s TippecanoeLaboratories in Lafayette, Ind., in 2010 and had been supplying the drug company with active pharmaceutical ingredients (APIs). Its plan was to convert the huge site into a contract manufacturing base in the U.S. Now that . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society